drugset / Trial / NCT06619886
TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor
Phase 0
Not yet recruiting
9 enrolled
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of T cell therapy with mutated TP53 R248Q specific TCR transduction in patients with advanced solid tumor expressing the TP53 R248Q mutation and the HLA-A\*11:01 allele.
Timeline
- Start
- 2024-09-24
- Primary completion
- 2026-10-31
- Completion
- 2027-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TP53-R248Q mutant TCR-T Cells | Cell therapy | — | Other |